Apparent Bone Lesions Not Tied to Enzalutamide Failure in Prostate Cancer
In certain men with metastatic castration-resistant prostate cancer (mCRPC) undergoing treatment with enzalutamide, unconfirmed lesions detected on follow-up bone scans may not be bode ill, according to a secondary analysis of phase 3 clinical trials.